Coronado Industries Team Gears up for a Full Schedule at Leading U.S. Ophthalmology Meeting; Will Discuss Wider Distribution of Their PNT Glaucoma Treatment with U.S. and International Distributors.

FOUNTAIN HILLS, Ariz. -- Coronado Industries Inc. (OTC BB: CDIK), the manufacturers of unique proprietary pneumatic devices for the non-invasive treatment of glaucoma through its wholly owned subsidiary, Ophthalmic International, said today that the company will be fielding a strong team led by Coronado Chairman Richard Smith and John Sharkey, president of Ophthalmic International, at the American Society of Cataracts and Refractory Surgery Show (ASCRS), in Washington, D.C., on April 15-20.

Smith said he and Dr. Sharkey have planned a full schedule of meetings with registration consultants and distributors and would be moving forward with ongoing discussions to broaden distribution of the firm's PNT technology in various overseas markets and current discussions and win FDA approval in the United States.

Smith said the ASCRS meeting attracts the very best of American ophthalmic surgeons and administrators and is the perfect environment in which to win industry approval for its patented glaucoma treatment in world markets.

"We are delighted as well, that our Dr. John LiVecchi has been invited to speak at the Glaucoma Symposium on Friday when he will be providing an overview of our latest research and development activities with PNT. It's the perfect audience to present all of the many virtues of the PNT procedure compared to multiple pharmaceutical and invasive surgical approaches for the treatment of open angle and pigmentary glaucoma and the ways in which we feel that it can improve the treatment of today's glaucoma patients, in this and many other countries around the world."

Dr. Sharkey, president of Ophthalmic International and director of operations for Coronado Industries, said their meetings with the company's FDA consultants, ClinReg Consulting Services, was particularly opportune. "We are focused on moving forward in our ongoing discussions with the FDA in order to obtain final approval to distribute the PNT treatment in the U.S.," he said.

"In addition, we have a full schedule of meetings with many excellent companies who are interested in taking up U.S. and foreign distribution of PNT. Altogether, it's an excellent occasion for us to consolidate the hard-won progress we have made in recent months and to put into place some more key components for our furthering growth in the U.S. and abroad. Our aim is to continue to build on the invaluable research that we are gaining from our European distributors as well as sales revenues."

Coronado Industries focuses on the development and commercialization of its patented PNT procedure as a cost-effective treatment of the most common types of glaucoma, which are open angle and pigmentary, as well as for the treatment of ocular hypertension.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.